论文部分内容阅读
Background: Aberrant expression of the RON receptor tyrosine kinase,a member of the MET proto-oncogene family,in breast cancer and non-small cell lung cancer (NSCLC) has therapeutic implication.Here we evaluated the efficacy of a novel anti-RON antibody-drug maytansinoid conjugate Zt/g4-DM1 for treatment of breast and NSCLC xenograft tumors in mouse models and explored a treatment strategy by combination of Zt/g4-DM1 with chemotherapeutics to achieve the maximal therapeutic activity.